Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

Helicobacter pylori research: historical insights and future directions

Nature Reviews Gastroenterology & Hepatology volume 10, pages 495–500 (2013)Cite this article

Subjects

Abstract

Helicobacter pylori leads to chronic gastritis, peptic ulcer disease and gastric cancer. With increasing issues of antibiotic resistance and changing epidemiology of this pathogen, new approaches are needed for effective management. In 1984, Dr Barry Marshall and Dr Robin Warren reported the association of Helicobacter pylori with peptic ulcers in The Lancet—a discovery that earned them the Nobel prize in Physiology or Medicine in 2005—but what progress have we made since then? Here, we have invited three international experts to give their insights into the advances in H. pylori research over the past 30 years and where research should be focused in the future.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. [No authors listed] Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the evaluation of carcinogenic risks to humans. Lyon, 7–14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 61, 1–241 (1994).

  2. Parkin, D. M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030–3044 (2006).

    CAS  PubMed  Google Scholar 

  3. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49, 347–353 (2001).

    Article  Google Scholar 

  4. Fock, K. M. et al. Asia–Pacific consensus guidelines on gastric cancer prevention. J. Gastroenterol. Hepatol. 23, 351–365 (2008).

    Article  PubMed  Google Scholar 

  5. Lee, Y. C. et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 62, 676–682 (2013).

    Article  PubMed  Google Scholar 

  6. Graham, D. Y. & Asaka, M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J. Gastroenterol. 45, 1–8 (2010).

    Article  PubMed  Google Scholar 

  7. Comfort, M. W. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. Ann. Intern. Med. 36, 1331–1348 (1951).

    Google Scholar 

  8. Cotton, P. NIH consensus panel urges antimicrobials for ulcer patients, skeptics concur with caveats. JAMA 271, 808–809 (1994).

    Article  CAS  PubMed  Google Scholar 

  9. Graham, D. Y., Lu, H. & Yamaoka, Y. Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 68, 725–736 (2008).

    Article  CAS  PubMed  Google Scholar 

  10. Warren, J. R. & Marshall, B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 321, 1273–1275 (1983).

    Article  Google Scholar 

  11. Marshall, B. J. & Warren, J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311–1315 (1984).

    Article  CAS  PubMed  Google Scholar 

  12. Malfertheiner, P., Chan, F. K. & McColl, K. E. Peptic ulcer disease. Lancet 374, 1449–1461 (2009).

    Article  CAS  PubMed  Google Scholar 

  13. Amieva, M. R. & El-Omar, E. M. Host–bacterial interactions in Helicobacter pylori infection. Gastroenterology 134, 306–323 (2008).

    Article  CAS  PubMed  Google Scholar 

  14. Wotherspoon, A. C., Ortiz-Hidalgo, C., Falzon, M. R. & Isaacson, P. G. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338, 1175–1176 (1991).

    Article  CAS  PubMed  Google Scholar 

  15. Ruskoné-Fourmestraux, A. et al. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 60, 747–758 (2011).

    Article  PubMed  Google Scholar 

  16. Nakamura, S. et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 61, 507–513 (2012).

    Article  PubMed  Google Scholar 

  17. Hatakeyama, M. Helicobacter pylori and gastric carcinogenesis. J. Gastroenterol. 44, 239–248 (2009).

    Article  CAS  PubMed  Google Scholar 

  18. Correia, M., Machado, J. C. & Ristimäki, A. Basic aspects of gastric cancer. Helicobacter 14 (Suppl. 1), 36–40 (2009).

    Article  CAS  PubMed  Google Scholar 

  19. Mizuno, S. et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig. Dis. Sci. 55, 3132–3137 (2010).

    Article  PubMed  Google Scholar 

  20. Vakil, N. & Megraud, F. Eradication therapy for Helicobacter pylori. Gastroenterology 133, 985–1001 (2007).

    Article  CAS  PubMed  Google Scholar 

  21. Tepes, B., O'Connor, A., Gisbert, J. P. & O'Morain, C. Treatment of Helicobacter pylori infection. Helicobacter 17 (Suppl. 1), 36–42 (2012).

    Article  CAS  PubMed  Google Scholar 

  22. Malfertheiner, P. et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report. Gut 61, 646–664 (2012).

    Article  CAS  PubMed  Google Scholar 

  23. Blaser, M. J. Equilibria of humans and our indigenous microbiota affecting asthma. Proc. Am. Thorac. Soc. 9, 69–71 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  24. Kobayashi, I. et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J. Clin. Microbiol. 45, 4006–4010 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ang, T. L. et al. Is there still a role for empiric first-line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. J. Dig. Dis. 14, 100–104 (2013).

    Article  CAS  PubMed  Google Scholar 

  26. Liou, J. M. et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 381, 205–213 (2013).

    Article  PubMed  Google Scholar 

  27. Graham, D. Y. & Rimbara, E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J. Clin. Gastroenterol. 45, 309–313 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  28. Rimbara, E., Fischbach, L. A. & Graham, D. Y. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 8, 79 (2011).

    Article  CAS  PubMed  Google Scholar 

  29. Vécsei, A. et al. Stool polymerase chain reaction for Helicobacter pylori detection and clarithromycin susceptibility testing in children. Clin. Gastroenterol. Hepatol. 8, 309–312 (2010).

    Article  PubMed  Google Scholar 

  30. Zhang, S., Moise, L. & Moss, S. F. H. pylori vaccines: why we still don't have any. Hum. Vaccin. 7, 1153–1157 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Moss, S. F. et al. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 29, 2085–2091 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kabir, S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 12, 89–102 (2007).

    Article  CAS  PubMed  Google Scholar 

  33. Del Giudice, G., Malfertheiner, P. & Rappuoli, R. Development of vaccines against Helicobacter pylori. Expert Rev. Vaccines 8, 1037–1049 (2009).

    Article  CAS  PubMed  Google Scholar 

  34. Aebischer, T. et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 57, 1065–1072 (2008).

    Article  CAS  PubMed  Google Scholar 

  35. Malfertheiner, P. et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 135, 787–795 (2008).

    Article  CAS  PubMed  Google Scholar 

  36. Bühling, A., Radun, D., Muller, W. A. & Malfertheiner, P. Influence of anti-Helicobacter triple therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. Aliment. Pharmacol. Ther. 15, 1445–1452 (2001).

    Article  PubMed  Google Scholar 

  37. Lee, Y. Y., Mahendra Raj, S. & Graham, D. Y. Helicobacter pylori infection—a boon or a bane: lessons from studies in a low-prevalence population. Helicobacter http:///dx.doi.org/10.1111/hel.12058.

  38. Liu, Y., Akiyama, J. & Graham, D. Y. Current understandings of Helicobacter pylori, peptic ulcer and gastroesophageal reflux disease. Minerva Gastroenterol. Dietol. 52, 235–248 (2006).

    CAS  PubMed  Google Scholar 

  39. Bik, E. M. et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc. Natl Acad. Sci. USA 103, 732–737 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Osaki, T. et al. Comparative analysis of gastric bacterial microbiota in Mongolian gerbils after long-term infection with H. pylori. Microb. Pathog. 53, 12–18 (2012).

    Article  PubMed  Google Scholar 

  41. Graessler, J. et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. J. Pharmacogenomics http://dx.doi.org/10.1038/tpj.2012.43.

  42. Jakobsson, H. et al. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand. J. Infect. Dis. 39, 757–763 (2007).

    Article  CAS  PubMed  Google Scholar 

  43. Thirumurthi, S. & Graham, D. Y. Helicobacter pylori infection in India from a western perspective. Indian J. Med. Res. 136, 549–562 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Fock, K. M. et al. Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 24, 1587–1600 (2009).

    Article  PubMed  Google Scholar 

  45. Strugatsky, D. et al. Structure of the proton-gated urea channel from the gastric pathogen Helicobacter pylori. Nature 493, 255–258 (2013).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

K. M. Fock has received grants from Health Sector Development Programme and National Medical Research Council. The author would also like to acknowledge assistance from Dr T. L. Ang in the preparation of this manuscript. D. Y. Graham is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338 (which funds the Texas Medical Center Digestive Diseases Center), DK067366 and CA116845. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the Veterans Affairs or NIH.

Author information

Author notes

  1. K. M. Fockkwong_ming_fock@cgh.com.sg

  2. D. Y. Graham dgraham@bcm.edu

  3. P. Malfertheinerpeter.malfertheiner@med.ovgu.de

Authors and Affiliations

  1. Changi General Hospital, 2 Semei Street 3, Singapore, 529889

    Kwong Ming Fock

  2. Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, 77030, TX, USA

    David Y. Graham

  3. Otto-von-Guericke-Universtität, Leipziger Strasse 44, Magdeburg, 39120, Germany

    Peter Malfertheiner

Authors
  1. Kwong Ming Fock
    View author publications

    Search author on:PubMed Google Scholar

  2. David Y. Graham
    View author publications

    Search author on:PubMed Google Scholar

  3. Peter Malfertheiner
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

K. M. Fock declares no competing interests. D. Y. Graham is an unpaid consultant for Novartis in relation to vaccine development for treatment or prevention of H. pylori infection. D. Y. Graham is also a paid consultant for RedHill Biopharma regarding novel H. pylori therapies and for Otsuka Pharmaceuticals regarding diagnostic testing. He has received royalties from Baylor College of Medicine for patents covering materials related to 13C-urea breath test. P. Malfertheiner is paid to give lectures at symposia related to H. pylori infection and acid-related disorders from AstraZeneca, Falk Foundation and Takeda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fock, K., Graham, D. & Malfertheiner, P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol 10, 495–500 (2013). https://doi.org/10.1038/nrgastro.2013.96

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrgastro.2013.96

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing